Breast Cancer Experts Suggest Minimum Benefit For New pCR Surrogate
Executive Summary
Pathologic complete response in neoadjuvant breast cancer trials is reasonably likely to result in better long-term outcomes, but how big the pCR improvement needs to be is a matter of guesswork.
You may also be interested in...
Plea To FDA: Set Realistic Bar For New Breast Cancer Trial Endpoint
Commenting on FDA’s draft guidance for accelerated approval using a relatively new surrogate marker of pathologic complete response, Roche/Genentech is wary that FDA may expect too high a bar for results. BIO asks FDA to consider safety when evaluating “magnitude of benefit.”
FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.